Cover Image


Analyzing the Global Diabetes Market 2016

出版商 Aruvian's R'search 商品編碼 231122
出版日期 內容資訊 英文 200 Pages
Back to Top
全球糖尿病市場相關分析 Analyzing the Global Diabetes Market 2016
出版日期: 2016年02月01日 內容資訊: 英文 200 Pages





  • 市場概要
  • 市場分析:各類藥物
  • 產業的市場區隔
  • 產業的主要產品


  • 市場概要
  • 胰島素注射液市場


  • α-葡萄糖苷酶抑制劑
  • 雙胍類(Biguanides )
  • DPP-4 抑制劑
  • Glitazone
  • GLP-1 受體激動劑
  • 磺醯尿素類(Sulfonylureas)
  • DPP-4 vs. GLP-1


  • Bydureon
  • Dapagliflozin
  • Degludec
  • 葡萄糖激酶活化劑
  • Lixisenatide
  • Syncria
  • Tradjenta
  • Victoza


  • 胰島素治療領域的研究
  • 體內的特定因素所扮演的角色的相關臨床上的證據
  • 糖尿病治療的心血管風險因素的應對
  • 美國的FDA的心血管風險的評估指南


  • 市場概要
  • 產業所面對的課題


  • 市場概要
  • 產業所面對的課題



  • Eli Lilly & Co.
  • Merck & Co.
  • Novo Nordisk
  • Sanofi SA
  • 武田藥品工業


  • 主要的抗糖尿病產品的預測
  • 主要的抗糖尿病分子的預測





Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. Oral anti-diabetics were the leading category of drugs in 2014 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.

Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.

Top players in the global diabetes market are Novo Nordisk, Eli Lilly, Merck & Co., amongst others. Significant R&D has been observed in the pre-insulin market leading to the development of several novel and safer therapies. The comparative performance of these therapies, such as the DPP-IV inhibitors and GLP-1 analogs is expected to shape the diabetes market landscape in the long term.

Aruvian Research analyzes the Global Diabetes Market in its research offering Analyzing the Global Diabetes Market. The report is a comprehensive analysis of the global diabetes industry.

The report begins with an introduction to diabetes. We analyze the basics of diabetes such as the different types of diabetes including Type 1 diabetes, Type 2 diabetes, gestational diabetes, and others. Complications with diabetes, how the disease is diagnosed, how the extent of diabetes is estimated, diabetes pathophysiology, and the treatment for diabetes are analyzed in this section. We also look at diabetes epidemiology.

Moving to the next section, we analyze the global diabetes market through a market overview and an analysis of the market by diabetes drug classes. We take the drug classes to be insulin, insulin secretagogues, insulin sensitizers, and incretin mimetics. We also analyze the industry through industry segmentation and an analysis of the leading industry products such as Lantus, Actos, Januvia, Novorapid, and others. We look at the sales figures of the leading 20 products in the industry.

An analysis of the global diabetes industry is not complete without an analysis of the market for insulin. We analyze the market for insulin through an industry overview, and an analysis of the market for human insulin. Within the market for human insulin we analyze the following market segments: fast-acting human insulin analogs, intermediate-acting human insulin analogs, long-acting human insulin analogs, and intermediate and fast-acting human insulin analogs.

With the rapid advances in technology, it is no wonder that there are now many novel emerging drug classes available for the treatment of diabetes. Some of these novel emerging drug classes for diabetes treatment are analyzed in our report. We analyze alpha-glucosidase inhibitors such as Basen, biguanides such as glucophages, DPP-IV inhibitors such as Januvia, glitazones such as Actos, GLP-1 agonists such as Victoza and Byetta, sulfonylureas such as Amaryl, amongst others.

Moving on, we carry out an analysis of some of the key molecules used in the treatment of diabetes today. Some of the molecules analyzed include Degludec, Victoza, Syncria, amongst others.

An analysis of the diabetes market in India and China, two of the countries with the largest prevalence of diabetes, is also included, along with a look at industry research and development.

Competition in the industry is analyzed in the report, following which we move on to the analysis of the major players in the global diabetes industry. Players in the industry are analyzed through a corporate profile, an analysis of their major business segments, their major products and services offered, a financial analysis, and an analysis of their presence in the diabetes market. We also look at their diabetes R&D pipeline, along with the company strategy for future growth in the diabetes industry. A SWOT analysis of the players completes the analysis of the major industry contributors.

Future perspective of the global diabetes market completes this in-depth profile of the global diabetes market from Aruvian Research.

Table of Contents

A. Executive Summary

B. Introduction to Diabetes

  • B.1. What is Diabetes?
  • B.2. Type 1 Diabetes
  • B.3. Type 2 Diabetes
  • B.4. Gestational Diabetes
  • B.5. Other Types of Diabetes (Pre-diabetes)
  • B.6. Complications with Diabetes
  • B.7. Diagnosing Diabetes
  • B.8. Estimating the Extent of Diabetes
  • B.9. Diabetes Pathophysiology
  • B.10. Treatment for Diabetes
  • B.11. Diabetes Epidemiology

C. Global Diabetes Market

  • C.1. Market Overview
  • C.2. Market Analysis by Diabetes Drug Classes
    • C.2.1. Insulin
    • C.2.2. Insulin Secretagogues
    • C.2.3. Insulin Sensitizers
    • C.2.4. Incretin Mimetics
  • C.3. Industry Segmentation
  • C.4. Leading Industry Products

D. Market for Insulin

  • D.1. Market Overview
  • D.2. Market for Human Insulin
    • D.2.1. Market for Fast-acting Human Insulin Analogs
    • D.2.2. Market for Intermediate-acting Human Insulin Analogs
    • D.2.3. Market for Long-acting Human Insulin Analogs
    • D.2.4. Market for Intermediate and Fast-acting Human Insulin Analogs

E. Analysis of Novel Emerging Drug Classes for Diabetes Treatment

  • E.1. Alpha-glucosidase Inhibitors
    • E.1.1. Product Analysis: Basen
  • E.2. Biguanides
    • E.2.1. Product Analysis: Glucophage
  • E.3. DPP-IV Inhibitors
    • E.3.1. Product Analysis: Januvia
  • E.4. Glitazones
    • E.4.1. Product Analysis: Actos
    • E.4.2. Product Analysis: Avandia
  • E.5. GLP-1 Agonists
    • E.5.1. Product Analysis: Victoza
    • E.5.2. Product Analysis: Byetta
  • E.6. Sulfonylureas
    • E.6.1. Product Analysis: Amaryl
  • E.7. DPP-IV versus GLP-1

F. Analysis of Key Molecules

  • F.1. Bydureon
  • F.2. Dapagliflozin
  • F.3. Degludec
  • F.4. Glucokinase Activators
  • F.5. Lixisenatide
  • F.6. Syncria
  • F.7. Tradjenta
  • F.8. Victoza

G. Industry Research & Development

  • G.1. Research on Insulin Therapy Areas
  • G.2. Clinical Evidence on the Role of Certain Elements in the Body
  • G.3. Addressing Cardiovascular Risk Factors in Diabetes Treatment
  • G.4. US FDA Cardiovascular Risk Evaluation Guidelines

H. Diabetes Market in India

  • H.1. Market Overview
  • H.2. Challenges Facing the Industry

I. Diabetes Market in China

  • I.1. Market Overview
  • I.2. Challenges Facing the Industry

J. Competition in the Industry

K. Leading Industry Contributors

  • K.1. Eli Lilly & Co.
    • K.1.1. Corporate Profile
    • K.1.2. Business Segment Analysis
    • K.1.3. Major Products & Services
    • K.1.4. Financial Analysis
    • K.1.5. Presence in the Diabetes Market
    • K.1.6. Diabetes R&D Pipeline
    • K.1.7. Company Strategy in the Global Diabetes Market
    • K.1.8. SWOT Analysis
  • K.2. Merck & Co.
    • K.2.1. Corporate Profile
    • K.2.2. Business Segment Analysis
    • K.2.3. Major Products & Services
    • K.2.4. Financial Analysis
    • K.2.5. Presence in the Diabetes Market
    • K.2.6. Diabetes R&D Pipeline
    • K.2.7. Company Strategy in the Global Diabetes Market
    • K.2.8. SWOT Analysis
  • K.3. Novo Nordisk
    • K.3.1. Corporate Profile
    • K.3.2. Business Segment Analysis
    • K.3.3. Major Products & Services
    • K.3.4. Financial Analysis
    • K.3.5. Presence in the Diabetes Market
    • K.3.6. Diabetes R&D Pipeline
    • K.3.7. Company Strategy in the Global Diabetes Market
    • K.3.8. SWOT Analysis
  • K.4. Sanofi SA
    • K.4.1. Corporate Profile
    • K.4.2. Business Segment Analysis
    • K.4.3. Major Products & Services
    • K.4.4. Financial Analysis
    • K.4.5. Presence in the Diabetes Market
    • K.4.6. Diabetes R&D Pipeline
    • K.4.7. Company Strategy in the Global Diabetes Market
    • K.4.8. SWOT Analysis
  • K.5. Takeda Pharmaceutical Company
    • K.5.1. Corporate Profile
    • K.5.2. Business Segment Analysis
    • K.5.3. Major Products & Services
    • K.5.4. Financial Analysis
    • K.5.5. Presence in the Diabetes Market
    • K.5.6. Diabetes R&D Pipeline
    • K.5.7. Company Strategy in the Global Diabetes Market
    • K.5.8. SWOT Analysis

L. Global Diabetes Market: Future Perspective

  • L.1. Forecast for Top Anti-diabetic Products
  • L.2. Forecast for Top Anti-diabetic Molecules

M. Glossary of Terms

List of Figures

  • Figure 1: Production of Insulin
  • Figure 2: Algorithm for Treatment of Diabetes
  • Figure 3: Market Share of Diabetes by Country (%), 2014
  • Figure 4: Various Diabetes Drug Classes and their Market Position in 2014
  • Figure 5: How GLP-1 Agonists Work
  • Figure 6: How Degludec Works
  • Figure 7: Overview of Degludec
  • Figure 8: Mechanism of Glucose Phosphorylation
  • Figure 9: How GK Activators in Type 2 Diabetes Work
  • Figure 10: Unmet Needs in Diabetes Treatment
  • Figure 11: Prevalence of Diabetes in India in 2014
  • Figure 12: Diabetes Products of Eli Lilly by Drug Class in 2014
  • Figure 13: Diabetes Products of Novo Nordisk by Drug Class in 2014
  • Figure 14: Diabetes Products of Sanofi SA by Drug Class in 2014
  • Figure 15: Diabetes Products of Takeda Pharmaceutical by Drug Class in 2014

List of Tables

  • Table 1: Prevalence of Diabetes by Region (2014-2030)
  • Table 2: Diabetes Prevalence in Leading 20 Countries, 2014 & 2030
  • Table 3: Sales of Anti-diabetic Drugs by Class (USD Million), 2014
  • Table 4: Diabetes Market Segmentation by Drug Class (USD Million) 2014-2020
  • Table 5: Leading 10 Diabetes Products (Sales & Market Share) (USD Million) 2014
  • Table 6: More Leading Diabetes Products (Sales & Market Share) (USD Million), 2014
  • Table 7: Different Types of Insulin Available & their Characteristics
  • Table 8: Sales of Human Insulin by Segments (USD Million), 2014
  • Table 9: Market Leaders in Fast-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2014
  • Table 10: Characteristics of Humalog by Eli Lilly
  • Table 11: Characteristics of NovoRapid by Novo Nordisk
  • Table 12: Table 9: Market Leaders in Intermediate-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2014
  • Table 13: Market Leaders in Long-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2014
  • Table 14: Characteristics of Lantus by Sanofi
  • Table 15: Market Leaders in Intermediate & Fast-Acting Insulin Class (Sales & Leading Brands) (USD Million), 2014
  • Table 16: Characteristics of NovoMix by Novo Nordisk
  • Table 17: Major Products & their Sales in the Alpha Glucosidase Inhibitors Drug Class (USD Million) in 2014
  • Table 18: Major Products & their Sales in the Biguanides Drug Class (USD Million) in 2014
  • Table 19: Major Products & their Sales in the DPP-IV Drug Class (USD Million) in 2014
  • Table 20: Factors Impacting the Market for Januvia
  • Table 21: Major Products & their Sales in the Glitazone Drug Class (USD Million) in 2014
  • Table 22: Major Products & their Sales in the GLP-1 Analogue Drug Class (USD Million) in 2014
  • Table 23: Major Products & their Sales in the Sulfonylureas Drug Class (USD Million) in 2014
  • Table 24: Comparison of GLP-1 Agonists and DPP-IV Inhibitors
  • Table 25: Phase III Clinical Trials Results of Dapagliflozin
  • Table 26: Sales of Market Leaders in 2014
  • Table 27: Anti-diabetic Products of Eli Lilly in 2014 (Sales & Market Share)
  • Table 28: Anti-diabetic Products of Merck & Co. in 2014 (Sales & Market Share)
  • Table 29: Diabetes R&D Pipeline of Merck & Co.
  • Table 30: Anti-diabetic Products of Novo Nordisk in 2014 (Sales & Market Share)
  • Table 31: Diabetes R&D Pipeline of Novo Nordisk
  • Table 32: Anti-diabetic Products of Sanofi SA in 2014 (Sales & Market Share)
  • Table 33: Diabetes R&D Pipeline of Sanofi SA
  • Table 34: Anti-diabetic Products of Takeda Pharmaceutical in 2014 (Sales & Market Share)
  • Table 35: Diabetes R&D Pipeline of Takeda Pharmaceutical
  • Table 36: Leading Anti-Diabetic Products Sales Forecast (USD Million) (2014-2020)
  • Table 37: Leading Anti-Diabetic Molecules Sales Forecast (USD Million) (2014-2020)
Back to Top